Stonepine Capital Management LLC Purchases New Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Stonepine Capital Management LLC acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 25,000 shares of the biopharmaceutical company’s stock, valued at approximately $120,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in VNDA. JPMorgan Chase & Co. grew its position in shares of Vanda Pharmaceuticals by 16.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 22,249 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Vanda Pharmaceuticals by 26.8% during the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 5,459 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Vanda Pharmaceuticals by 4.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock worth $3,925,000 after purchasing an additional 38,449 shares in the last quarter. Monaco Asset Management SAM grew its position in shares of Vanda Pharmaceuticals by 92.8% during the 4th quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock worth $1,879,000 after purchasing an additional 188,836 shares in the last quarter. Finally, American Century Companies Inc. grew its position in shares of Vanda Pharmaceuticals by 2.1% during the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company’s stock worth $1,438,000 after purchasing an additional 6,079 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Up 5.9%

Shares of Vanda Pharmaceuticals stock opened at $4.16 on Friday. The company has a 50 day moving average of $4.43 and a 200-day moving average of $4.63. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $6.75. The company has a market cap of $245.17 million, a PE ratio of -13.00 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The business had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was purchased at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the transaction, the chief executive officer now owns 2,361,730 shares in the company, valued at $11,241,834.80. The trade was a 0.43% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased a total of 32,000 shares of company stock valued at $151,180 in the last quarter. Insiders own 10.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on VNDA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Finally, StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.